We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 02, 2021

Ramucirumab Plus Erlotinib in Metastatic NSCLC With EGFR Ex19del and Ex21L858R Mutations

Clinical Cancer Research


Additional Info

Clinical Cancer Research
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer
Clin. Cancer Res 2021 Jul 22;[EPub Ahead of Print], K Nakagawa, E Nadal, EB Garon, M Nishio, T Seto, N Yamamoto, K Park, JY Shih, L Paz-Ares, B Frimodt-Moller, AH Zimmermann, S Wijayawardana, C Visseren-Grul, M Reck

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading